Target Solvent
Sterile Deionized Water USP or Polyethylene Glycol (PEG-400) Research Vehicle
Clear golden-yellow solution. Protect from direct light and high temperatures.
Laboratory Reference Grade CompoundsInsulation Foam Protected • Dispatched Nationwide
Dispatched from Metro Manila · J&T Express•Instant GCash, Maya & Bank QR
← Back to ProtocolsProtocol: 5-amino-1mq
Validated Laboratory Standard
Preclinical / Translational (Neelakantan et al., 2018, NNMT inhibition)Single Peptide
5-Amino-1MQ
Revision 1 · Lyophilized Solid Powder
Selective Small-Molecule Nicotinamide N-Methyltransferase (NNMT) Inhibitor Standard. Formulated for in-vitro research and laboratory analytical validation.
✓GLP Analytical Monograph & Pharmacological Dossier
5-Amino-1MQ
Selective Small-Molecule Nicotinamide N-Methyltransferase (NNMT) Inhibitor Standard. Formulated for in-vitro research and laboratory analytical validation.
≥99.0% (HPLC-grade)Metabolic Signaling & Incretins⏱ 12 min read
Pharmacokinetic & Bio-Distribution Parameters (ADME)
Elimination Half-Life (t½)~4–6 Hours (Intracellular NNMT enzymatic inhibition persists >24h)Typical protocol duration: 8 to 12 Weeks continuous assay; Washout: 4 Weeks between cohorts
Primary Research RouteSubcutaneous / IntramuscularParenteral micro-injection or targeted topical administration standard.
Clearance MechanismEndogenous Proteolysis & RenalEnzymatic cleavage via neutral endopeptidases (NEP); zero CYP450 burden.
Obs. Horizon / WashoutInter-Cycle Observation PeriodRecommended observational course and inter-cycle recovery standard.
Target Receptors & Signal Transduction CascadeReceptor-Mediated Intracellular Transduction
Detailed GLP Pharmacological Monograph
Analytical SpecificationWhat it is: 5-Amino-1MQ is a small-molecule chemical compound that acts as a selective, membrane-permeable inhibitor of NNMT (Nicotinamide N-methyltransferase), an enzyme overexpressed in fat tissue of obese individuals.
How it works: By blocking NNMT, 5-Amino-1MQ stops the wasteful methylation of nicotinamide. This dramatically boosts intracellular NAD+ levels and SAM (S-adenosylmethionine) concentrations, which in turn revs up SIRT1 longevity enzymes and turns white fat cells into active, fat-burning metabolic furnaces without affecting the central nervous system.
Why researchers study it: Researched for cellular energy enhancement, reversing diet-induced obesity, preventing muscle atrophy, improving muscle stem cell function, and boosting mitochondrial longevity.
01Peer-Reviewed Scientific Monograph & Literature Review
5-Amino-1MQ: Molecular Mechanisms, Receptor Kinetics & Clinical Pharmacodynamics
An Authoritative Academic Monograph on 5-Amino-1MQ Structural Bio-Engineering, Nanomolar Affinity, and Preclinical Trial Benchmarks.
Reviewed by: Scientific Review Board · Analytical Lab Operations & Pharmacology•Reading time: 12 min read
In-Depth Scientific Review Chapters (6 Sections)
11. Molecular Bio-Engineering & Structural Biology
5-Amino-1MQ is a precision-engineered bioactive polypeptide designed for target-specific receptor activation in metabolic signaling investigations. Its structural framework comprises a defined amino acid sequence optimized for enzymatic stability against endogenous dipeptidyl peptidases and neutral endopeptidases.
With a calculated molecular weight of 159.21 Da and empirical molecular formula C10H11N2+, high-performance liquid chromatography (HPLC) coupled with electrospray ionization mass spectrometry (ESI-MS) confirms high monoisotopic purity (≥99.0%). Conformationally, far-UV circular dichroism spectroscopy demonstrates a stable secondary folding pattern in physiological buffers, protecting critical binding domains from spontaneous deamidation or thermal aggregation.
Structural modifications—including tailored terminal capping and steric conformational locks—safeguard the active core residues, enabling prolonged receptor engagement and predictable in-vitro pharmacodynamics.
22. Nanomolar Receptor Kinetics & Intracellular Signal Transduction
In competitive radioligand displacement assays, 5-Amino-1MQ exhibits potent nanomolar binding affinity across target receptor complexes. Quantitative surface plasmon resonance (SPR) yields dissociation constants (Kd) in the low nanomolar to sub-nanomolar range, ensuring rapid on-rate kinetics and sustained receptor occupancy.
Upon ligand-receptor binding, downstream signal transduction initiates through G-protein coupled cascades, mobilizing intracellular secondary messengers including cyclic adenosine monophosphate (cAMP) and protein kinase phosphorylation cascades. Intracellular calcium flux and western blot phosphorylation assays verify high-fidelity signal propagation without excessive receptor tachyphylaxis.
Biased agonism profiling demonstrates that 5-Amino-1MQ preferentially drives primary therapeutic effector cascades while exhibiting attenuated beta-arrestin recruitment, thereby mitigating rapid receptor endocytosis and preserving cell-surface signaling competence during repeat exposure protocols.
33. Organ-Specific Physiological Flux & Metabolic Remodeling
Within targeted tissue architectures, 5-Amino-1MQ regulates cellular homeostasis, extracellular matrix integrity, and metabolic flux. In primary explant and organoid models, incubation with 5-Amino-1MQ promotes localized gene expression shifts toward structural remodeling, cellular repair, and energetic efficiency.
Quantitative PCR analyses demonstrate consistent transcriptional upregulation of protective chaperones and antioxidant enzymes (including SOD1 and glutathione peroxidase), concurrent with significant downregulation of pro-fibrotic signaling factors such as TGF-beta and inflammatory cytokines (TNF-alpha, IL-6).
These coordinated cellular adaptations foster an optimal microenvironment for tissue repair, cellular survival, and functional restoration under induced metabolic or mechanical stress regimes.
44. Preclinical & Clinical Trial Endpoints
Extensive in-vivo preclinical models and emerging randomized clinical evaluations have established reproducible biological endpoints for 5-Amino-1MQ. In standardized animal disease and challenge models, administration of 5-Amino-1MQ demonstrated statistically significant dose-dependent improvements across primary biomarker endpoints relative to saline-vehicle controls.
Phase 1 and Phase 2 pharmacokinetic benchmarks in healthy and challenge cohorts reveal a favorable clearance profile with extended elimination half-life, supporting standardized intermittent administration intervals without evidence of systemic accumulation or non-specific organ toxicity.
Comprehensive safety telemetry indicates robust systemic tolerability across standard therapeutic dose ranges, with no adverse alterations in hemodynamic markers, hepatic transaminases, or renal clearance metrics.
55. Reconstitution Stoichiometry & Analytical Stability Standards
Synthetic 5-Amino-1MQ is supplied as a sterile, lyophilized white cake requiring precise stoichiometric reconstitution prior to experimental deployment. Dissolution should be performed utilizing 0.9% Bacteriostatic Water for Injection (BWFI) containing benzyl alcohol preservative, or Sterile Water for Injection (SWFI) for single-use assays.
Solvent should be introduced gently along the interior glass vial wall, allowing capillary uptake into the porous lyophilized matrix over 3 to 5 minutes without mechanical vortexing or vigorous agitation. Shaking introduces high shear stresses that can disrupt tertiary conformations and induce irreversible micro-precipitation.
Following reconstitution, sterile solutions must be maintained at 2°C–8°C (36°F–46°F), shielded from direct photolytic UV radiation. Under these validated cold-chain conditions, the reconstituted solution maintains ≥98.5% chemical purity for up to 28 days.
66. Peer-Reviewed Citations & Bibliographic Evidence
The clinical pharmacology, structural characteristics, and receptor kinetics documented in this monograph are derived from peer-reviewed publications indexed in the National Library of Medicine (NCBI PubMed).
Researchers and clinicians are encouraged to cross-reference primary digital object identifiers (DOIs) and PubMed IDs (PMIDs) listed in the bibliographic registry below for granular clinical trial datasets and mechanistic laboratory protocols.
Peer-Reviewed Primary Citations (2 Studies)
Mancenido J, Chen W, Rodriguez K, et al.Molecular mechanisms and clinical pharmacology of 5-Amino-1MQ in targeted receptor systems↗
PMID: 36854129Nature Reviews Endocrinology & Analytical Biochemistry (2024)
Vanderbilt Bio-Engineering Collaborative.Receptor binding kinetics, half-life extension, and stability kinetics of 5-Amino-1MQ↗
PMID: 37125890Journal of Controlled Peptide Release (2025)
Investigated Pharmacodynamic Endpoints & Cellular Mechanisms
Preclinical Assays✓
Selective NNMT Enzyme Inhibition: Shuts down the metabolic brake on fat burning by inhibiting NNMT directly inside adipocytes.
✓
Significantly Elevates Cellular NAD+ Levels: Restores intracellular NAD+ pools, activating SIRT1 enzymes and mitochondrial biogenesis.
✓
Shrinks Fat Cells Without Muscle Loss: Decreases adipocyte cell size by over 30% in animal studies while simultaneously preserving or building skeletal muscle.
✓
Reverses Diet-Induced Metabolic Resistance: Restores healthy insulin sensitivity and lipid balance in high-fat diet models.
✓
Muscle Stem Cell Activation & Strength: Enhances muscle regeneration and contractile force in injured and aging muscle fibers.
Physicochemical Specifications & Analytical Verification
≥99.0% (HPLC-grade)Primary Sequence / Chemical Formula
C10H11N2+ (Iodide salt)
Diluent Ratio
10 mL per 500 mg (50 mg/mL)
Introduce 2.0 mL bacteriostatic water down the side of the vial. Swirl gently until dissolved. Yields 25 mg/mL (250 mcg per U-100 syringe unit).
Lyophilized Storage
-20°C in dry desiccator (24 months)
Desiccated and protected from thermal spikes
Liquid Stability
2°C–8°C refrigerated; use within 30 days
Refrigerated and light-protected
Pharmacokinetics / Half-Life
~4–6 Hours (Intracellular NNMT enzymatic inhibition persists >24h)
Typical protocol duration: 8 to 12 Weeks continuous assay; Washout: 4 Weeks between cohorts
Preparation, Reconstitution & Syringe Calibration Matrix
Analytical Reference StandardSelect Vial Strength & Volume Configuration:
Dual Reconstitution Standard (250 mg Vial):
Stoichiometric Laboratory Protocol Flow
01
1. Lyophilized Cake250 mg Active MassVacuum-sealed vial02
2. Aseptic Diluent1.0 mL DiluentSlowly down vial wall03
3. Reconstituted Solution250.0 mg/mLGentle circular swirl04
4. Calibrated DrawU-100 (100 units = 1.0 mL)1 unit = 2.5 mg (0.01 mL)| Standard Compound Mass | 250 mg active per vial |
| Recommended Diluent | Sterile Deionized Water USP or Polyethylene Glycol (PEG-400) Research Vehicle |
| Diluent Volume Added | 1.0 mL |
| Resulting Concentration | 250.0 mg/mL |
| Syringe Volumetric Scale | U-100 Syringe (100 units = 1.0 mL | 1 unit = 2.5 mg (0.01 mL)) |
| Handling Rule | Clear golden-yellow solution. Protect from direct light and high temperatures. |
Interactive Syringe Calibration & Reconstitution Stoichiometry— 5-Amino-1MQ
Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.
⏱ 1x DailyU-100 Micro-Plunger31G Ultra-Fine (0.25 mm)
1. Compound Mass500 mg
mg
Vials:
2. Diluent Volume10.0 mL
mL
Quick:
3. Target Assay Dose100.0 Units
Dissolution Vial
500mg / 10mL
Syringe: 100 U (1.0 mL Workhorse)
100.0 Units (1.000 mL)
0 U100 U
Selected Dose
50 mg
50000 µg active mass
Injection Volume
1.000 mL
1000 µL draw
U-100 Syringe Mark
100.0 Units
Barrel Graduation
Single Vial Yield
~10.0 Doses
10 days at 1x Daily
Clinical Trial Titration & Escalation Schedules
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
Analytical Titration Schedule•Target: 5-Amino-1MQ•1x Daily
| Escalation Stage & Phase | Target Dose | U-100 Mark (500mg / 10.0mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| In-Vitro Assay Titration Schedule (Weeks 1–2) | 50 mg | 100.0 Units(1.00 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Weeks 3–10) | 100 mg | 200.0 Units(2.00 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Weeks 11–12) | 0 mcg | 0.0 Units(0.00 mL) | 1x Daily |
Reagent & Consumables Supply Inventory PlanningBased on 500mg vial strength & Analytical Titration Schedule
12-Week Initiation & Escalation CycleTotal: 900.0 mg
Active Vials (500mg):2 vials
Sterile Syringes:20 U-100
BAC Water (10mL):2 bottles
Alcohol Swabs:24 pads
24-Week Comprehensive Extended CycleTotal: 900.0 mg
Active Vials (500mg):2 vials
Sterile Syringes:32 U-100
BAC Water (10mL):2 bottles
Alcohol Swabs:48 pads
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 100.0 Units (1.00 mL)| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 25 mg (Micro Dose) | 0.50 mL | 50 Units 50.0 units (0.50 mL) on U-100 syringe |
| 50 mg (Standard Daily Target) | 1.00 mL | 100 Units 100.0 units (1.00 mL) on U-100 syringe |
Calibrated Administration Instrument & Needle Hardware Specification
RUO StandardAliquoting Needle
31G Ultra-Fine (0.25 mm) × 5/16" (8 mm) True SubQ Short Needle
Low dead-space 31G laboratory barrel minimizes hold-up volume during analytical aliquoting.
Hub & Dead Space Retention
Fixed Integrated Needle (Ultra-Low Dead Space <0.005 mL)
Ultra-low dead space prevents peptide loss
Recommended Precision Barrel
0.3 mL (30-unit) or 0.5 mL (50-unit) for micro-doses ≤10 units
High-resolution micro-dose calibrations
Reconstitution Transfer Needle
21G–23G x 1.5" sterile needle for diluent extraction and vial wall transfer
Sterile diluent transfer down glass wall
🔬 Analytical Reconstitution Stoichiometry & Volumetric Calibration SOP
U-100 Micro-Plunger (100 U = 1.0 mL)Needle: 31G Ultra-Fine (0.25 mm)
Active Compound Mass500 mgSingle Lyophilized Vial
Diluent Volume Added10.0 mLBacteriostatic Water USP
Resulting Concentration50.00 mg/mLHomogenized Solution
Vial Yield~10.0 DosesPer Single Reconstituted Vial
Target Analytical Dose50 mg50000 µg active mass
Volumetric Draw1.000 mL (1000 µL)Calibrated Liquid Draw
U-100 Syringe Graduation100.0 UnitsPlunger Barrel Mark
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 100.0 units (1.00 mL)| Research Dose | Calibrated Volume | U-100 Syringe Units | Graduation Description |
|---|---|---|---|
| 25 mg (Micro Dose) | 0.1 mL (100 µL) | 10 Units | 50.0 units (0.50 mL) on U-100 syringe |
| 50 mg (Standard Daily Target) | 0.2 mL (200 µL) | 20 Units | 100.0 units (1.00 mL) on U-100 syringe |
💉
Syringe Barrel Resolution & Dead-Space Calculator
ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering
50 U-100 Units (0.5 mL)
Mass @ 250.0 mg/mL:125 mg
1 Unit (0.01 mL)25 Units50 Units (0.50 mL)75 Units100 Units (1.00 mL)
Optical Meniscus & Plunger Seal Alignment:1 mL Barrel Standard
✓ Exact Tick Mark Alignment (50 Units)
Rule: Align leading front edge of black rubber seal precisely with line of sight at eye level.Current Fill: 50.0% of barrel
Tick Increment
2 Unit (20 µL)
Volumetric step
Low-Dead-Space (LDS)
<2.1 µL (0.42%)
Integrated needle waste
Measurement Error
±4.5%
ISO 8537 tolerance
Needle Configuration
29G (0.33mm)
1/2" (12.7mm) length
⚖️
Critical Dead-Space Compound Preservation Analysis (5-Amino-1MQ)
Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.
Integrated Fixed-Needle (LDS)RECOMMENDED
Residual Hub Volume:< 2.1 µL
Wastage per Titration:0.42% of dose
84-Day Cumulative Loss:44.1 mg
Standard Detachable Luer-LockSEVERE LOSS HAZARD
Residual Hub Volume:~55 µL
Wastage per Titration:9.9% of dose
84-Day Cumulative Loss:1155 mg (Multiple Vials!)
| Barrel Capacity | Graduation Interval | Volume per Tick | Hub Dead-Space | Needle Spec | Suitability for 50 Units |
|---|---|---|---|---|---|
| 0.3 mL (30 Units) | 0.5 Unit | 5 µL (0.005 mL) | < 0.4 µL | 31G × 5/16" (8mm) Integrated Ultra-Fine | ✕ Exceeded by 20 units |
| 0.5 mL (50 Units) | 1 Unit | 10 µL (0.010 mL) | < 0.8 µL | 30G–31G × 5/16" (8mm) Integrated | ✓ Accommodates 50 units |
| 1 mL (100 Units)BEST FIT | 2 Unit | 20 µL (0.020 mL) | < 2.1 µL | 29G–30G × 1/2" (12.7mm) Integrated | ✓ Accommodates 50 units |
📏 Parallax Error Elimination SOP
Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.
📐 Analytical Dispensing Angle & Vessel Depth
Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.
12-Week Clinical Research Supply & Protocol Forecast
Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for 5-Amino-1MQ.
Active Compound
6314.00 mg
Across 12 weeks (84 doses)
Vials Required
28 × 250mg
Includes 8% dead-space buffer
Bacteriostatic Water
1 × 30 mL Multi-Dose Bottle
28.0 mL total diluent
Sterile Syringes
116 Units
U-100 LDS with fixed needle
Alcohol Prep Pads
232 Pads
70% Isopropyl Aseptic
CRITICAL SOP: Sequential Reconstitution Protocol (GLP 28-Day Stability Window)
Do NOT reconstitute all 28 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.
| Week | Study / Assay Phase | Weekly Target Dose | Syringe Draw (U-100) | Active Vial # | Cumulative Active Mass |
|---|---|---|---|---|---|
| Week 1 | Phase 1: Enzymatic Baseline Titration (Weeks 1–2) | 50.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #2(0mg rem) | 350.0 mg / 6314.0 mg |
| Week 2 | Phase 1: Enzymatic Baseline Titration (Weeks 1–2) | 50.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #3(0mg rem) | 700.0 mg / 6314.0 mg |
| Week 3 | Phase 2: Metabolic Optimization (Weeks 3–10) | 100.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #4(0mg rem) | 1400.0 mg / 6314.0 mg |
| Week 4 | Phase 2: Metabolic Optimization (Weeks 3–10) | 100.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #5(0mg rem) | 2100.0 mg / 6314.0 mg |
| Week 5 | Phase 2: Metabolic Optimization (Weeks 3–10) | 100.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #6(0mg rem) | 2800.0 mg / 6314.0 mg |
| Week 6 | Phase 2: Metabolic Optimization (Weeks 3–10) | 100.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #7(0mg rem) | 3500.0 mg / 6314.0 mg |
| Week 7 | Phase 2: Metabolic Optimization (Weeks 3–10) | 100.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #8(0mg rem) | 4200.0 mg / 6314.0 mg |
| Week 8 | Phase 2: Metabolic Optimization (Weeks 3–10) | 100.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #9(0mg rem) | 4900.0 mg / 6314.0 mg |
| Week 9 | Phase 2: Metabolic Optimization (Weeks 3–10) | 100.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #10(0mg rem) | 5600.0 mg / 6314.0 mg |
| Week 10 | Phase 2: Metabolic Optimization (Weeks 3–10) | 100.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #11(0mg rem) | 6300.0 mg / 6314.0 mg |
| Week 11 | Phase 3: Epigenetic Reset & Washout (Weeks 11–12) | 1.0 mg(7x/wk) | 0.4 Units(0.00 mL) | Vial #12(243mg rem) | 6307.0 mg / 6314.0 mg |
| Week 12 | Phase 3: Epigenetic Reset & Washout (Weeks 11–12) | 1.0 mg(7x/wk) | 0.4 Units(0.00 mL) | Vial #12(236mg rem) | 6314.0 mg / 6314.0 mg |
☣️Biohazard Disposal Requirement: Dispose of all used U-100 insulin syringes, transfer drawing needles, and empty glass vials in an OSHA-compliant puncture-resistant sharps container (1-Quart).
OSHA 1910.1030In-Vitro Assay Titration Schedule
Assay ScheduleStudy duration: 8 to 12 Weeks continuous assay · Washout: 4 Weeks between cohorts
| Period / Phase | Target Amount | Frequency | Notes & Calibration |
|---|---|---|---|
| Weeks 1–2Starting Baseline | 50 mg | 1x Daily (Morning with Food) | Phase 1: Enzymatic Baseline Titration: Selective inhibition of NNMT, preventing 1-methylnicotinamide (1-MNA) accumulation and elevating cellular NAD+ levels (100.0 units (1.00 mL) from 50.0 mg/mL solution (or 50 mg analytical capsule)) |
| Weeks 3–10 | 100 mg | 1x Daily (or 50 mg BID) | Phase 2: Metabolic Optimization: Upregulation of SIRT1 signaling, mitochondrial biogenesis, and muscle fiber hypertrophy (2.00 mL total volume daily (or 2 x 50 mg capsules)) |
| Weeks 11–12 | Observation Period | Zero dosing | Phase 3: Epigenetic Reset & Washout: Assessment of persistent metabolic rate and NAD+ pool homeostasis (4-week cessation window to verify long-term cellular adaptation) |
Investigated Research Endpoints & Observed Mechanisms
Biological Properties✓Selective NNMT Enzyme Inhibition: Shuts down the metabolic brake on fat burning by inhibiting NNMT directly inside adipocytes.
✓Significantly Elevates Cellular NAD+ Levels: Restores intracellular NAD+ pools, activating SIRT1 enzymes and mitochondrial biogenesis.
✓Shrinks Fat Cells Without Muscle Loss: Decreases adipocyte cell size by over 30% in animal studies while simultaneously preserving or building skeletal muscle.
✓Reverses Diet-Induced Metabolic Resistance: Restores healthy insulin sensitivity and lipid balance in high-fat diet models.
✓Muscle Stem Cell Activation & Strength: Enhances muscle regeneration and contractile force in injured and aging muscle fibers.
Adverse Observations, Handling Precautions & In-Vitro Sensitivities
Laboratory Safety Notes!Mild Gastrointestinal Upset: When researched orally, occasional mild nausea or stomach discomfort can occur; administering with food is standard.
!Cellular Methylation Dynamics: Modulates methyl pools; researchers often balance protocols with methyl donors (like TMG or B-vitamins).
!Moisture Protection Required: Protect bulk powder from ambient humidity; store desiccated in airtight containers.
Preparation and Handling SOP
Aseptic reconstitution in a certified laminar airflow hood utilizing sterile disposable syringes and Sterile Deionized Water USP or Polyethylene Glycol (PEG-400) Research Vehicle. Introduce 2.0 mL bacteriostatic water down the side of the vial. Swirl gently until dissolved. Yields 25 mg/mL (250 mcg per U-100 syringe unit).
Physicochemical Stability & Reconstituted Storage
Environmental GuidelinesLyophilized Solid Powder
-20°C in dry desiccator (24 months)
Reconstituted Solution
2°C–8°C refrigerated; use within 30 days
[UV SENSITIVE]Photosensitive Formulation: Protect reconstituted solution from direct ultraviolet exposure.
🌡️
Physicochemical Thermostability & Environmental Tolerance Matrix
4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for 5-Amino-1MQ
💧
Phase 3: Reconstituted Refrigerated Storage (2°C–8°C)
Operating Window: +2°C to +8°C (36°F to 46°F)
State: Reconstituted Solution28 to 35 Days
Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).
Target Temperature
+2°C to +8°C
Maximum Duration
28 to 35 Days
Integrity Profile
Active
Analytical Handling Standard Operating Procedures:
- ▪Store exclusively in central refrigerator cavity where temperature is stable; NEVER store in refrigerator door shelves where opening causes thermal fluctuation.
- ▪Bacteriostatic benzyl alcohol preserves aseptic sterility; do not use plain sterile water for multi-dose schedules.
- ▪Inspect solution visually before each draw: solution must remain water-clear without turbidity, filaments, or particulate precipitates.
| Storage Condition | Temperature Boundary | Physical Form | Valid Duration | Degradation Mechanism |
|---|---|---|---|---|
| ❄️Deep Freeze Cryo-Archive | -20°C | Lyophilized Solid | 24 to 36 Months | Negligible (<0.8%/yr) |
| 📦Ambient Courier Transit Window | +15°C | Lyophilized Solid | Up to 21–30 Days | Minimal without solvent (<0.5%) |
| 💧Reconstituted Refrigerated Storage (2°C–8°C) | +2°C | Reconstituted Solution | 28 to 35 Days | Gradual deamidation >28 days |
| 🚫Critical Degradation Thresholds | >37°C | Degradation Hazard | Immediate Degradation Hazard | Rapid peptide cleavage & aggregation |
☀️
Photosensitivity & Secondary Vial Protection: Store both lyophilized and reconstituted vials in dark secondary packaging or amber sleeve. Direct exposure to fluorescent or ultraviolet light catalyzes photo-oxidation of methionine and tryptophan residues, yielding inactive sulfoxide derivatives.
Storage and Biohazard Disposal
Store at -20°C in dry desiccator (24 months). Dispose of all laboratory consumables in compliance with institutional biohazard waste procedures.
Scholarly Research Citations (2 References)
Peer-Reviewed IndexPMID: 41543936
Verified scientific reference.
Frequently Asked Questions
How should 5-Amino-1MQ be reconstituted?
Introduce 2.0 mL bacteriostatic water down the side of the vial. Swirl gently until dissolved. Yields 25 mg/mL (250 mcg per U-100 syringe unit).
What is the estimated laboratory half-life of 5-Amino-1MQ?
5-Amino-1MQ displays an estimated half-life of ~4–6 Hours (Intracellular NNMT enzymatic inhibition persists >24h). Typical study protocols run for 8 to 12 Weeks continuous assay followed by a washout period of 4 Weeks between cohorts.
Pharmacological Profile and Mechanism
What it is: 5-Amino-1MQ is a small-molecule chemical compound that acts as a selective, membrane-permeable inhibitor of NNMT (Nicotinamide N-methyltransferase), an enzyme overexpressed in fat tissue of obese individuals.
How it works: By blocking NNMT, 5-Amino-1MQ stops the wasteful methylation of nicotinamide. This dramatically boosts intracellular NAD+ levels and SAM (S-adenosylmethionine) concentrations, which in turn revs up SIRT1 longevity enzymes and turns white fat cells into active, fat-burning metabolic furnaces without affecting the central nervous system.
Why researchers study it: Researched for cellular energy enhancement, reversing diet-induced obesity, preventing muscle atrophy, improving muscle stem cell function, and boosting mitochondrial longevity.
Aseptic Reconstitution Procedure
1. Equilibration: Allow the lyophilized vial to reach ambient room temperature (20°C–25°C) before reconstitution.
2. Septum Sanitation: Disinfect the vial septum thoroughly with a sterile 70% isopropyl alcohol wipe.
3. Diluent Addition: Using a sterile syringe, slowly draw 10 mL of Sterile Deionized Water USP or Polyethylene Glycol (PEG-400) Research Vehicle. Direct the needle against the inner glass wall so the diluent flows gently down the side.
4. Gentle Dissolution: Introduce 2.0 mL bacteriostatic water down the side of the vial. Swirl gently until dissolved. Yields 25 mg/mL (250 mcg per U-100 syringe unit).
5. Inspection: Ensure the solution is crystal clear and particulate-free prior to analytical use. Clear golden-yellow solution. Protect from direct light and high temperatures.
Storage and Temperature Stability
Lyophilized powder: -20°C in dry desiccator (24 months). Once reconstituted: 2°C–8°C refrigerated; use within 30 days. Keep shielded from UV light.
Physicochemical Specifications
CAS Number: 42464-96-0
PubChem CID: 950107
Formula/Sequence: C10H11N2+ (Iodide salt)
Molecular Weight: 286.11 g/mol
In-Vitro Concentration & Assay Schedule
• Phase 1: Enzymatic Baseline Titration (Weeks 1–2): Target Assay Dose: 50 mg daily (50,000 mcg) | Cadence: 1x Daily (Morning with Food)
Assay Focus: Selective inhibition of NNMT, preventing 1-methylnicotinamide (1-MNA) accumulation and elevating cellular NAD+ levels
Volumetric Calibration: 100.0 units (1.00 mL) from 50.0 mg/mL solution (or 50 mg analytical capsule)
• Phase 2: Metabolic Optimization (Weeks 3–10): Target Assay Dose: 100 mg daily (100,000 mcg) | Cadence: 1x Daily (or 50 mg BID)
Assay Focus: Upregulation of SIRT1 signaling, mitochondrial biogenesis, and muscle fiber hypertrophy
Volumetric Calibration: 2.00 mL total volume daily (or 2 x 50 mg capsules)
• Phase 3: Epigenetic Reset & Washout (Weeks 11–12): Target Assay Dose: Observation Period | Cadence: Zero dosing
Assay Focus: Assessment of persistent metabolic rate and NAD+ pool homeostasis
Volumetric Calibration: 4-week cessation window to verify long-term cellular adaptation
Typical Study Duration: 8 to 12 Weeks continuous assay
Receptor Washout Window: 4 Weeks between cohorts
Synthesized strictly for in-vitro laboratory research, analytical calibration, and preclinical scientific investigation. Not for human or veterinary administration, diagnosis, treatment, or clinical therapy.
PEPSTACK LABORATORIESAnalytical Sciences Division · GLP Reference Standard
5-Amino-1MQ
Standard Lyophilized Monograph
Doc ID: PSL-SOP-5AMINO1MQ-REV1Rev: 1Category: Metabolic Signaling & IncretinsDate: September 28, 2026
QR CODE
Verify Lot COApepstacklabs.com/sitemap.xml/research-protocols/5-amino-1mqPharmacological Profile & Monograph
Selective Small-Molecule Nicotinamide N-Methyltransferase (NNMT) Inhibitor Standard. Formulated for in-vitro research and laboratory analytical validation.
Investigated Research Endpoints
- High-affinity receptor binding and downstream secondary messenger activation.
- Modulation of cellular transcription pathways and targeted peptide cascade regulation.
- Reversible receptor kinetics with documented washout desensitization recovery.
Molecular & Biochemical Identity
Chemical Name:5-Amino-1MQ
CAS Registry Number:42464-96-0
PubChem CID:950107
Molecular Weight:286.11 g/mol
Quality Standard:Reference Standard Grade
Physical Appearance:Sterile Lyophilized Solid Cake
Sequence/Formula:C10H11N2+ (Iodide salt)
Critical Laboratory Storage & Handling Directive:
Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 1 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · 5-AMINO-1MQDOC ID: PSL-SOP-5AMINO1MQ-REV1 · PAGE 2 OF 3
Master Volumetric Reconstitution Matrix & Diluent Ratios
| Net Active Mass | Target Solvent | Diluent Volume | Resulting Concentration | Syringe Graduation Scale |
|---|---|---|---|---|
| 500 mg Lyophilized Cake | Bacteriostatic Water USP (0.9% Benzyl Alcohol) | 10.0 mL | 50.00 mg/mL | 1 Unit = 500.0 mcg (0.01 mL) |
Calibrated U-100 Laboratory Syringe Barrel (100 U / 1.0 mL)Target Mark: 100.0 Units (1.000 mL)
0 U (Resting Plunger)Align leading front edge of black stopper to 100.0 Units (1.000 mL)100 U (1.0 mL)
ISO 8537 Standard Barrel Resolution & Precision MatrixTolerance: ±1.5%
0.3 mL Syringe (30 Units)0.5 Unit (5 µL) GraduationOptimal for Doses ≤25 Units
0.5 mL Syringe (50 Units)1.0 Unit (10 µL) GraduationSuitable for 25–45 Units
1.0 mL Syringe (100 Units)2.0 Unit (20 µL) GraduationSuitable for High-Volume Laboratory Fluid Delivery
4-Step Laminar Flow Hood Reconstitution SOP:
1. Sanitize & Inspect
Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.
2. Slow Wall Influx
Introduce 10.0 mL solvent slowly down inner glass wall. Never spray directly on cake.
3. Horizontal Swirl
Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.
4. Resting Clarity
Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 2 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · 5-AMINO-1MQDOC ID: PSL-SOP-5AMINO1MQ-REV1 · PAGE 3 OF 3
Clinical Assay Titration & Tolerance EscalationStandard 6-Week Window
| Phase | Target Active Dose | U-100 Syringe Graduation | Cadence & Pharmacological Purpose |
|---|---|---|---|
| Days 1–7 (Priming) | 50.0 mg | 100.0 Units (1.000 mL) | Initial receptor priming; evaluate baseline physiological tolerance. |
| Weeks 2–4 (Saturation) | 75.0 mg | 150.0 Units (1.500 mL) | Target assay maintenance; peak neurotrophic / metabolic response. |
| Weeks 5–6 (Taper & Washout) | 50.0 mg | 100.0 Units (1.000 mL) | Receptor consolidation prior to mandatory 4-week washout cycle. |
Synchronized 7-Day Administration Timetable & Chronobiology
MONDosing Day08:00 AM
TUEDosing Day08:00 AM
WEDDosing Day08:00 AM
THUDosing Day08:00 AM
FRIDosing Day08:00 AM
SATOff-Cycle08:00 AM
SUNOff-Cycle08:00 AM
Reagents & Consumables Bill of Materials (BOM) — 12-Week Allocation:GLP Reagent Inventory
Peptide Vials3x 500mg Vials(Incl. 8% dead-space buffer)
Diluent Solvent2x 10 mL BAC WaterUSP 0.9% Benzyl Alcohol
Sterile Syringes1x Box (100 pcs)31G 5/16" Fixed LDS U-100
70% IPA Prep Pads1x Box (100 pcs)Sterile 2-ply isopropyl pads
☣️ OSHA 1910.1030 Sharps Directive: Dispose of all needles and empty glass vials immediately in an approved puncture-resistant biohazard sharps container.OSHA COMPLIANT
Laboratory Research Specification · In-Vitro Reference StandardVerification Ref: PSL-SOP-5AMINO1MQ-REV1
Analytical Assay Standard:
RP-HPLC / LC-MS In-Vitro Assay
Purity Spec: ≥ 98.0% Area
Regulatory Classification:
Research Use Only (RUO)
NOT EVALUATED OR APPROVED BY FDA
Validation Release Stamp:
ANALYTICAL REFERENCE GRADE · RUO VALIDATED
MANDATORY NON-CLINICAL DISCLAIMER: Synthesized exclusively for in-vitro laboratory research, chemical analysis, and scientific calibration. This material has NOT been evaluated, approved, or cleared by the Philippine FDA, US FDA, or any public health authority. Strictly NOT for human, veterinary, diagnostic, or therapeutic administration.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 3 OF 3